Literature DB >> 20215128

Comparison of the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks versus streptomycin for 2 weeks plus doxycycline for 45 days in the treatment of human brucellosis: a randomized clinical trial.

M R Hasanjani Roushan1, M J Soleimani Amiri, N Janmohammadi, M Sadeghi Hadad, M Javanian, M Baiani, A Bijani.   

Abstract

OBJECTIVES: To compare the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks with streptomycin for 2 weeks plus doxycycline for 45 days in the treatment of human brucellosis.
METHODS: In each arm of the study, 82 patients older than 10 years randomly received 5 mg/kg gentamicin once daily for 5 days plus 100 mg of doxycycline twice daily for 8 weeks or 1 g of streptomycin intramuscularly for 2 weeks plus the same dose of doxycycline for 45 days. Therapeutic failure and relapse in these two treatment groups were compared. This study was registered in the Iranian Registry of Clinical Trials (www.irct.ir) with registration number ID: IRCT138708191441N1.
RESULTS: The clinical manifestations in these two groups were similar. Therapeutic failure was seen in two (2.4%) patients in the gentamicin/doxycycline group and in four (4.9%) patients in the streptomycin/doxycycline group [relative risk (RR) = 0.5, 95% confidence interval (CI) 0.09-2.66, P = 0.68]. Relapse was seen in two (2.4%) cases in the gentamicin/doxycycline group and in five (6.1%) cases in the streptomycin/doxycycline group (RR = 0.4, 95% CI 0.08-2, P = 0.44). The efficacy with the gentamicin/doxycycline regimen was 95.12% and that with the streptomycin/doxycycline regimen was 89% (RR = 1.07, 95% CI 0.98-1.17, P = 0.25). Cox regression analyses showed no differences among the two treatment groups for patients who had relapse or therapeutic failure and those who had not regarding baseline covariates such as sex, duration of disease before diagnosis, positive blood culture and focal disease.
CONCLUSIONS: The results show that the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks is not superior to that of streptomycin for 2 weeks plus doxycycline for 45 days.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20215128     DOI: 10.1093/jac/dkq064

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Hydrophobic gentamicin-loaded nanoparticles are effective against Brucella melitensis infection in mice.

Authors:  Edurne Imbuluzqueta; Carlos Gamazo; Hugo Lana; Miguel Ángel Campanero; David Salas; Ana Gloria Gil; Elisa Elizondo; Nora Ventosa; Jaume Veciana; María J Blanco-Prieto
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

2.  Polymerase Chain Reaction-Based Assays for the Diagnosis of Active and Relapsed Cases of Human Brucellosis.

Authors:  Mohammad Reza Hasanjani Roushan; Seyed Mahmoud Amin Marashi; Zahra Moulana
Journal:  Am J Trop Med Hyg       Date:  2016-10-24       Impact factor: 2.345

3.  Single intra-articular injection of adeno-associated virus results in stable and controllable in vivo transgene expression in normal rat knees.

Authors:  K A Payne; H H Lee; A M Haleem; C Martins; Z Yuan; C Qiao; X Xiao; C R Chu
Journal:  Osteoarthritis Cartilage       Date:  2011-04-28       Impact factor: 6.576

4.  Treatment of brucellosis: a systematic review of studies in recent twenty years.

Authors:  Seyed Mohammad Alavi; Leila Alavi
Journal:  Caspian J Intern Med       Date:  2013

Review 5.  The current therapeutical strategies in human brucellosis.

Authors:  Mile Bosilkovski; Fariba Keramat; Jurica Arapović
Journal:  Infection       Date:  2021-03-01       Impact factor: 3.553

Review 6.  Brucellosis in low-income and middle-income countries.

Authors:  Matthew P Rubach; Jo E B Halliday; Sarah Cleaveland; John A Crump
Journal:  Curr Opin Infect Dis       Date:  2013-10       Impact factor: 4.915

Review 7.  Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis.

Authors:  Julián Solís García del Pozo; Javier Solera
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

8.  Risk Factors for Relapse of Human Brucellosis.

Authors:  Mohammad Reza Hasanjani Roushan; Zahra Moulana; Zeinab Mohseni Afshar; Soheil Ebrahimpour
Journal:  Glob J Health Sci       Date:  2015-11-03

9.  Venous thrombosis, peripheral aneurysm formation, and fever in a feral pig hunter with Brucellosis.

Authors:  Ivan Gowe; Christopher Parsons; Stephen Vickery; Michael Best; Scott Prechter; Marilyn Goss Haskell; Eveline Parsons
Journal:  IDCases       Date:  2022-02-10

10.  A foodborne outbreak of brucellosis at a police station cafeteria, Lima, Peru.

Authors:  Karina Román; Rosa Castillo; Robert H Gilman; Maritza Calderón; Aldo Vivar; Manuel Céspedes; Henk L Smits; Paolo Meléndez; Eduardo Gotuzzo; Humberto Guerra; Ryan C Maves; Michael A Matthias; Joseph M Vinetz; Mayuko Saito
Journal:  Am J Trop Med Hyg       Date:  2013-02-04       Impact factor: 2.345

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.